Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
AffiliationDepartment of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. firstname.lastname@example.org
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Receptor, Epidermal Growth Factor
Receptors, Vascular Endothelial Growth Factor
Vascular Endothelial Growth Factor A
MetadataShow full item record
CitationAntiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. 2010, 235 (1):3-9 Exp. Biol. Med. (Maywood)
JournalExperimental biology and medicine (Maywood, N.J.)
AbstractLung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
- Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
- Authors: Horn L, Sandler AB
- Issue date: 2009 Mar
- Drug insight: VEGF as a therapeutic target for breast cancer.
- Authors: Schneider BP, Sledge GW Jr
- Issue date: 2007 Mar
- Antiangiogenic drugs in non-small cell lung cancer treatment.
- Authors: Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F
- Issue date: 2006 Mar
- Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
- Authors: Hsu JY, Wakelee HA
- Issue date: 2009
- Targeting tumor neovasculature in non-small-cell lung cancer.
- Authors: Pallis AG, Syrigos KN
- Issue date: 2013 May